AU2017324935B2 - Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (NAFLD), NASH, ALD or conditions related to the liver - Google Patents

Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (NAFLD), NASH, ALD or conditions related to the liver Download PDF

Info

Publication number
AU2017324935B2
AU2017324935B2 AU2017324935A AU2017324935A AU2017324935B2 AU 2017324935 B2 AU2017324935 B2 AU 2017324935B2 AU 2017324935 A AU2017324935 A AU 2017324935A AU 2017324935 A AU2017324935 A AU 2017324935A AU 2017324935 B2 AU2017324935 B2 AU 2017324935B2
Authority
AU
Australia
Prior art keywords
ring containing
optionally substituted
liver disease
membered ring
nitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017324935A
Other languages
English (en)
Other versions
AU2017324935A1 (en
Inventor
Naji Abumrad
Charles Flynn
John Rathmacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MTI Biotech Inc
Original Assignee
MTI Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MTI Biotech Inc filed Critical MTI Biotech Inc
Publication of AU2017324935A1 publication Critical patent/AU2017324935A1/en
Assigned to MTI BIOTECH, INC. reassignment MTI BIOTECH, INC. Request for Assignment Assignors: METABOLIC TECHNOLOGIES, INC.
Application granted granted Critical
Publication of AU2017324935B2 publication Critical patent/AU2017324935B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pediatric Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2017324935A 2016-09-06 2017-09-06 Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (NAFLD), NASH, ALD or conditions related to the liver Active AU2017324935B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662383895P 2016-09-06 2016-09-06
US62/383,895 2016-09-06
US201662410133P 2016-10-19 2016-10-19
US62/410,133 2016-10-19
PCT/US2017/050317 WO2018048932A1 (en) 2016-09-06 2017-09-06 Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver

Publications (2)

Publication Number Publication Date
AU2017324935A1 AU2017324935A1 (en) 2019-03-28
AU2017324935B2 true AU2017324935B2 (en) 2021-10-21

Family

ID=61562136

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017324935A Active AU2017324935B2 (en) 2016-09-06 2017-09-06 Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (NAFLD), NASH, ALD or conditions related to the liver

Country Status (8)

Country Link
US (3) US20180153827A1 (https=)
EP (1) EP3510014B1 (https=)
JP (3) JP7189127B2 (https=)
CN (2) CN110177771B (https=)
AU (1) AU2017324935B2 (https=)
CA (1) CA3035897A1 (https=)
MX (1) MX2019002579A (https=)
WO (1) WO2018048932A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018201074A1 (en) * 2017-04-27 2018-11-01 Vanderbilt University Methods for treating atherosclerosis with gamma-ketoaldehyde scavengers
BR112020004372A2 (pt) * 2017-09-05 2020-09-08 Mti Biotech, Inc. método para tratar, prevenir ou melhorar fibrose hepática em um indivíduo.
PL3914359T3 (pl) 2019-01-25 2025-07-28 Mti Biotech, Inc. Pochodne salicyloaminy przyłączone do trifenylofosfonium
CN114344448A (zh) * 2022-01-20 2022-04-15 广西医科大学第一附属医院 Pmx-53多肽在制备治疗非酒精性脂肪性肝炎药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023063A2 (en) * 1998-10-22 2000-04-27 University Of South Carolina Methods for inhibiting diabetic complications
US20150265584A1 (en) * 2014-03-18 2015-09-24 Vanderbilt University Levuglandin adducts histone h4 in a cyclooxygenase-2-dependent manner, altering its interaction with dna

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1177796B1 (en) * 1999-04-27 2011-04-27 Mitsubishi Tanabe Pharma Corporation Medicament for prevention or therapeutic treatment of liver disease
CN1628650A (zh) * 2003-12-19 2005-06-22 刘力 复方二氯醋酸二异丙胺冻干粉针制剂及其制备方法
US8822542B2 (en) * 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
WO2008070778A2 (en) * 2006-12-06 2008-06-12 Nephrogenex Inc. Pyridoxamine and low molecular weight heparinoids for diabetic kidney disease
US20110117194A1 (en) 2008-04-29 2011-05-19 Hanall Biopharma Co., Ltd. Pharmaceutical formulation containing angiotensin-ii receptor blocker
US10975033B2 (en) 2011-07-12 2021-04-13 Vanderbilt University Methods for treating inflammation and hypertension with γ-ketoaldehyde skavengers
WO2013168013A2 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic diseases and inflammatory disorders
KR20170088883A (ko) * 2014-11-11 2017-08-02 벤더르빌트 유니버시티 급성 신장 손상을 제한하기 위한 방법
WO2017033119A1 (en) * 2015-08-25 2017-03-02 Rao M Surya Compositions and methods for the treatment of liver metabolic diseases
BR112020004372A2 (pt) * 2017-09-05 2020-09-08 Mti Biotech, Inc. método para tratar, prevenir ou melhorar fibrose hepática em um indivíduo.
US20210023032A1 (en) * 2017-09-05 2021-01-28 Mti Biotech, Inc. Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023063A2 (en) * 1998-10-22 2000-04-27 University Of South Carolina Methods for inhibiting diabetic complications
US20150265584A1 (en) * 2014-03-18 2015-09-24 Vanderbilt University Levuglandin adducts histone h4 in a cyclooxygenase-2-dependent manner, altering its interaction with dna

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROYCHOWDHURY et al., "Formation of r-ketoaldehyde-protein adducts during ethanol-induced liver injury in mice", Free Radical Biology and Medicine, (2009-07-17), vol. 47, no. 11, pages 1526 - 1538 *

Also Published As

Publication number Publication date
MX2019002579A (es) 2020-02-05
WO2018048932A1 (en) 2018-03-15
EP3510014A4 (en) 2020-05-20
JP2025032245A (ja) 2025-03-11
EP3510014B1 (en) 2026-04-29
JP2023022236A (ja) 2023-02-14
US20180153827A1 (en) 2018-06-07
CN119345198A (zh) 2025-01-24
US12383515B2 (en) 2025-08-12
JP7189127B2 (ja) 2022-12-13
EP3510014A1 (en) 2019-07-17
US20230181494A1 (en) 2023-06-15
CN110177771A (zh) 2019-08-27
CA3035897A1 (en) 2018-03-15
AU2017324935A1 (en) 2019-03-28
BR112019004404A2 (pt) 2019-05-28
JP2019526598A (ja) 2019-09-19
US20250360094A1 (en) 2025-11-27
CN110177771B (zh) 2022-12-13

Similar Documents

Publication Publication Date Title
US12383515B2 (en) Compositions and methods of use of γ-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (NAFLD), NASH, ALD or conditions related to the liver
Suzuki et al. Green coffee bean extract and its metabolites have a hypotensive effect in spontaneously hypertensive rats
Niu et al. Protective effect of gentiopicroside against dextran sodium sulfate induced colitis in mice
Seniutkin et al. Effects of pirfenidone in acute and sub-chronic liver fibrosis, and an initiation-promotion cancer model in the mouse
CN111182904A (zh) 包含acc抑制剂的组合治疗
Angoa-Pérez et al. Effects of combined treatment with mephedrone and methamphetamine or 3, 4-methylenedioxymethamphetamine on serotonin nerve endings of the hippocampus
Sharawy et al. Anti-fibrotic activity of sitagliptin against concanavalin A-induced hepatic fibrosis. Role of Nrf2 activation/NF-κB inhibition
El-Gazar et al. Elucidating PAR1 as a therapeutic target for delayed traumatic brain injury: Unveiling the PPAR-γ/Nrf2/HO-1/GPX4 axis to suppress ferroptosis and alleviate NLRP3 inflammasome activation in rats
Hu et al. Effect of Piper nigrum essential oil in dextran sulfate sodium (DSS)-induced colitis and its potential mechanisms
Diling et al. Docking studies and biological evaluation of a potential β-secretase inhibitor of 3-hydroxyhericenone F from Hericium erinaceus
Khazaei et al. Protective effects of sulfated polysaccharides from Enteromorpha intestinalis on oxidative stress, liver iron overload and Ferroptosis in Zebra fish exposed to ethanol
CN114007607A (zh) 用于治疗神经变性疾病的材料和方法
CN114470217B (zh) 预防和治疗代谢异常或炎症引起的组织损伤的药物组合物
HK40012573B (en) Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver
BR112019004404B1 (pt) Uso de um composto
HK40012573A (en) Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver
JP7441170B2 (ja) 肝臓の線維症を治療、予防、又は改善するためのγ－ケトアルデヒド捕捉剤の組成物とその使用の方法
Hao et al. Scoparone attenuates cholestatic liver injury through regulating hepatic bile acid metabolism, ameliorating periductal fibrosis and inhibiting inflammatory response
Wang et al. Arctigenin-mediated gut microbiota and metabolite butyric acid positively affect the intestinal barrier and hepatic lipid metabolism in diet-induced metabolic dysfunction-associated fatty liver disease
Oliveira N-Acetylcysteine (NAC): Impacts on Human Health
Tobin The Key to Diethylene Glycol Toxicity Lies in the Transport of Its Toxic Metabolite Diglycolic Acid
EP4731618A2 (en) Novel co-drug, co-administration, and sequential administration of selective ttr ligand and c20-d3-retinol
JP2023103420A (ja) 脂肪性肝疾患の治療薬
CN113194940A (zh) 治疗脂肪肝的包含单乙酰基二酰基甘油化合物的组合物
HK40024982A (en) Combination therapy comprising an acc inhibitor

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: MTI BIOTECH, INC.

Free format text: FORMER APPLICANT(S): METABOLIC TECHNOLOGIES, INC.

FGA Letters patent sealed or granted (standard patent)